Conducting a comprehensive meta-analysis can help address these discrepancies by systematically analyzing existing data, accounting for variables, and offering a clearer assessment of COX-2 potential as a predictor in CRC outcomes [16,18]. The gene discussed is PTGS2; the disease is colorectal carcinoma.